As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Society of Hematology must ensure balance, independence, objectivity, and scientific rigor in all of the educational activities it sponsors. All authors are expected to disclose any financial relationships with any proprietary entity producing health care goods or services that have occurred within 12 months from the start of or during the production of the work and which are relevant to the author’s content. If an author has such a financial interest, then s/he must disclose the name of the commercial interest and nature of the relationship (e.g., consultant, grantee, etc.). If the author has no such financial relationship, s/he must declare that s/he has nothing to disclose. The intent of this disclosure is not to prevent an author with a significant financial or other relationship from making a presentation, but rather to provide readers with information on which they can make their own judgments. It remains for the audience to determine whether the author’s interests or relationships may influence the work with regard to exposition or conclusion.

	Research support/Research	Consultant	Major stockholder	Speakers’ bureau	Scientific advisory board
Thomas C. Abshire, MD		Novo Nordisk, ZLB Behring, Bayer			Novo Nordisk, ZLB Behring, Bayer
Kenneth C. Anderson, MD	Millennium, Celgene, Novartis	Millennium, Celgene, Novartis		Millennium, Celgene, Novartis
George R. Buchanan, MD
Alan B. Cantor, MD, PhD
Mark A. Crowther, MD, MSc, FRCPC	Pfizer, Leo Laboratories			Pfizer, Leo Laboratories, Calea
Georgette A. Dent, MD
Henry C. Fung MD, FRCPE				Biogen Idec, Genentech, Millennium, Celgene
Francis J. Giles, MD
Stephanie A. Gregory, MD	Biogen Idec, Celgene, Genentech, Amgen, Millennium, Ortho Biotech, GlaxoSmithKline, Ligand, Berlex, Merck	Biogen Idec, Genentech, Amgen, Ortho Biotech, GlaxoSmithKline
Jay H. Herman, MD
Teru Hideshima, MD, PhD		Keryx Biopharmaceuticals
Meghan A. Higman, MD, PhD
Sima Jeha, MD	Sanofi Aventis	Genzyme		Genzyme
Marc J. Kahn, MD
Thomas R. Klumpp, MD, FACP
Cindy Leissinger, MD
Daniel C. Link, MD
Michael Linenberger, MD
Alice D. Ma, MD
Dana C. Matthews, MD		Wyeth
Keith R. McCrae, MD		Baxter		GlaxoSmithKline
Martha P. Mims, MD, PhD			Amgen, Biogen Idec
Josef T. Prchal, MD
Robert E. Richard, MD, PhD
Paul G. Richardson, MD		Celgene, Millennium		Celgene, Millennium
Nita L. Seibel, MD				Astellas, Enzon, Pfizer
Jamile M. Shammo, MD, FASCP		Celgene, Pharmion		Amgen, Ortho Biotech, Celgene, Pharmion
Kevin Shannon, MD
Akiko Shimamura, MD, PhD
Don L. Siegel, PhD, MD
Jamie E. Siegel, MD
Lewis R. Silverman, MD
David P. Steensma, MD, FACP
F. Marc Stewart, MD
Wendy Stock, MD	Berlex			Enzon
Mark M. Udden, MD	Amgen
Koen van Besien, MD	Millennium, Miltenyi Biotec, Genzyme	AnorMED		Millennium
Parameswaran Venugopal, MD				Genentech, Berlex
Ted Wun, MD, FACP	Icagen/McNeil Genentech	Genentech		Glaxo-Smith-Kline
Marc S. Zumberg, MD

In compliance with ACCME policy, the American Society of Hematology also requires all authors to disclose any discussion of off-label drug use.

Dr. Crowther will discuss the use of anticoagulants during pregnancy and outside of current licensed indications.
Dr. Higman will discuss multiple agents for pediatric oncology.
Dr. Jeha will discuss early-phase studies of different agents (published data).
Dr. Leissinger will discuss off-label dosing of epoetin alfa in HIV patients.
Dr. Linenberger will discuss the use of recombinant factor VIIa in non-hemophiliac patients.
Dr. Seibel will discuss chemotherapy used in treating children with ALL.
Dr. Shammo will discuss off-label uses of hematopoietic growth factors.
Dr. Steensma will discuss imatinib for HES/mastocytosis, 2C0A for HES, and anagrelide for non-ET thrombocytosis.
Dr. Stock will discuss the trials incorporating monoclonal antibodies, rituxan, and campath into front-line therapy for subsets of ALL.
Dr. Venugopal will discuss the use of rituximab in front-line therapy of lymphomas.
Dr. Wun will discuss the therapy of HLH, LCH, and mastocytosis that have not been labeled for that purpose.